Drug Profile
CCX 507
Alternative Names: CCX-507; CCX507 BLatest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator ChemoCentryx
- Class Anti-inflammatories; Small molecules
- Mechanism of Action CCR9 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Ulcerative colitis
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Ulcerative-colitis(In volunteers) in Netherlands (PO)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Ulcerative-colitis(In volunteers) in USA (PO)
- 22 Jan 2021 CCX 507 is in phase I development for Inflammatory bowel diseases (ChemoCentryx pipeline, January 2021)